Novartis is acquiring cancer treatment developer MorphoSys for 2.7 billion euros, adding a new rare bone-marrow cancer treatment to their portfolio. This deal will take MorphoSys private and is contingent on certain conditions. Novartis will own pelabresib, a promising drug used to fight deadly cancers. MorphoSys management recommends shareholders accept the offer and plan to file.